Mucosal immunity against influenza induced by attenuated recombinant Sendai virus. (October 2011)

• Record Type: Journal Article
• Authors: Imamura, Tadatsugu; Oshitani, Hitoshi
• Is Part Of: Expert review of vaccines. Volume 10:Number 10(2011)
• Page Start: 1393
• Page End: 1395
• Publication Date: 2011-10
• Subjects: influenza virus -- live-attenuated vaccine -- mucosal immunity -- recombinant virus -- Sendai virus; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/erv.11.123
• Languages: English
• ISSNs: 1476-0584

Abstract

Evaluation of: Le TV, Mironova E, Garcin D, Compans RW. Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One 6(4), e18780 (2011). Live-attenuated influenza vaccines (LAIVs) have been shown to be more immunogenic and capable of inducing a broader immune response than inactivated vaccine. However, use of LAIVs is still limited owing to the safety concerns. Le et al. generated an attenuated recombinant Sendai virus – GP42-H1 expressing the hemagglutinin (HA) gene of influenza A virus. The HA protein was expressed on the cell surface of CV-1 cells infected with GP42-H1. Intranasal immunization of mice with GP42-H1 induced HA-specific IgG and IgA antibodies in sera and mucosal sites without causing any disease symptoms. Immunized mice were also protected from lethal dose challenge of influenza A virus.